Journal
THORAX
Volume 71, Issue 2, Pages 161-170Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2015-207140
Keywords
-
Categories
Funding
- National Institute for Health Research, Health Technology Assessment (NIHR HTA) [HTA 09/61/01]
- Cambridge Biomedical Research Centre
- NIHR Clinical Research Network, Eastern
- National Institute of Health Research Senior Investigator Award
- Cambridge Cancer Centre
- National Institute for Health Research [09/61/01, 09/61/501, 07/82/01] Funding Source: researchfish
- National Institutes of Health Research (NIHR) [HTA/09/61/01] Funding Source: National Institutes of Health Research (NIHR)
Ask authors/readers for more resources
Background Lung cancer screening using low-dose CT (LDCT) was shown to reduce lung cancer mortality by 20% in the National Lung Screening Trial. Methods The pilot UK Lung Cancer Screening (UKLS) is a randomised controlled trial of LDCT screening for lung cancer versus usual care. A population-based questionnaire was used to identify high-risk individuals. CT screen-detected nodules were managed by a pre-specified protocol. Cost effectiveness was modelled with reference to the National Lung Cancer Screening Trial mortality reduction. Results 247 354 individuals aged 50-75 years were approached; 30.7% expressed an interest, 8729 (11.5%) were eligible and 4055 were randomised, 2028 into the CT arm (1994 underwent a CT). Forty-two participants (2.1%) had confirmed lung cancer, 34 (1.7%) at baseline and 8 (0.4%) at the 12-month scan. 28/42 (66.7%) had stage I disease, 36/42 (85.7%) had stage I or II disease. 35/42 (83.3%) had surgical resection. 536 subjects had nodules greater than 50 mm(3) or 5 mm diameter and 41/536 were found to have lung cancer. One further cancer was detected by follow-up of nodules between 15 and 50 mm3 at 12 months. The baseline estimate for the incremental cost-effectiveness ratio of once-only CT screening, under the UKLS protocol, was 8466 pound per quality adjusted life year gained (CI 5542 pound to 12 pound 569). Conclusions The UKLS pilot trial demonstrated that it is possible to detect lung cancer at an early stage and deliver potentially curative treatment in over 80% of cases. Health economic analysis suggests that the intervention would be cost effective-this needs to be confirmed using data on observed lung cancer mortality reduction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available